In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine.

The mothers of 52 fetuses with toxoplasma fetopathy diagnosed in utero were treated with a combination pyrimethamine-sulfa drug and spiramycine. Their infants were compared to a group of 51 infants whose mothers had received spiramycine alone. Postnatal treatment was identical in both groups.

[Fetal toxoplasmosis. In utero treatment with pyrimethamine sulfamides].

The mothers of 52 cases of toxoplasmic fetopathy diagnosed in utero by fetal blood and/or amniotic fluid sampling were treated with the combination pyrimethamine-sulfadiazine (or sulfisoxazole) and by spiramycine. The infants were compared with 51 other infants with congenital toxoplasmosis whose mothers had received spiramycine alone. Patients of both groups received the same pyrimethamine-sulfadiazine and spiramycine treatment after birth.

[Congenital toxoplasmosis. 5 cases of mother-to-child transmission of pre-pregnancy infection].

Five cases of congenital toxoplasmosis consecutive to a maternal toxoplasma infection that had preceded pregnancy were observed. One woman with normal immune system had developed a well-documented lymph node toxoplasmosis 2 months before conceiving. Four women had chronic toxoplasmosis diagnosed in the course of an immunosuppressive disease: Hodgkin's disease in 1 case, systemic lupus erythematosus in 2 cases and pancytopenia in 1 case.

Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection.

The results of parasitological investigation of the placenta for toxoplasma in 223 cases with documented congenital toxoplasmosis were analysed according to whether the mother had been treated, or not, with spiramycin during pregnancy. The investigation was negative in 10-11% of the cases when the mother had not been treated or had been inadequately treated; in 25% of the cases with a treatment of 3 g spiramycin day; and in 50% with spiramycin plus the combination of pyrimethamine with sulphonamide. This series is compared with a previous group of 321 women whose placental investigation was negative in 50% of untreated cases and 81% of treated women.

Antigen(s) responsible for immunoglobulin G responses specific for the acute stage of Toxoplasma infection in humans.

An agglutination test for immunoglobulin G (IgG) Toxoplasma antibodies with acetone-fixed tachyzoites (AC antigens; AC agglutination test) was positive only with sera from patients during the acute stage of their infection. In contrast, when the test was performed with Formalin-fixed tachyzoites (HS antigens; HS agglutination test), positive results were obtained during both the acute and chronic (latent) stages of the infection. Studies were performed to define the antigen(s) of T.